Skip to main content

nvx-cov2373

nvx-cov2373: 2 clinical trials tracked.

nvx-cov2373 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about nvx-cov2373, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

COVID-19
Clinical Trial Registry Records (2)

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Novavax COVID-19 Vaccine(s) as Second or Subsequent Booster After mRNA Vaccines in Individuals 18 to 49 Years of Age

NCT05875701Registry updated 2025-06-26·Phase 3·NVAX
Completed

Primary endpoint: Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Geometric Mean Titers (GMT)

InterventionalRandomizedopen147 enrolledStarted 2023-03Completion 2023-115 sites · United StatesNovavax

A Randomized, Observer-Blinded, Phase 3 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

NCT05463068Registry updated 2026-04-17·Phase 3·NVAX
Completed

Primary endpoint: Serum Immunoglobulin G (IgG) Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Geometric Mean ELISA Unit [GMEUs]

InterventionalRandomizedtriple911 enrolledStarted 2022-07Completion 2022-0930 sites · United StatesNovavax